Literature DB >> 9738666

Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12.

C Kanegane1, C Sgadari, H Kanegane, J Teruya-Feldstein, L Yao, G Gupta, J M Farber, F Liao, L Liu, G Tosato.   

Abstract

The mechanisms by which interleukin-12 (IL-12) exerts antitumor effects have been difficult to dissect. In this study, we examined the potential contribution of the chemokines interferon-gamma-inducible protein-10 (IP-10) and Mig to the antitumor effects of IL-12. Using an athymic mouse model, local inoculations with IL-12 consistently produced tumor size reductions associated with characteristic tumor necrosis and vascular damage. These effects were indistinguishable from those produced by IP-10 or Mig injected locally in the same tumor model. Local and systemic treatment with IL-12 was associated with expression of the interferon-gamma (IFN-gamma), IP-10, and Mig genes and proteins in the tumor. Levels of IP-10 and Mig expression in the tumor, the liver, and the kidney were inversely correlated with tumor size. Administration in vivo of neutralizing antibodies to IP-10 and Mig reduced substantially the antitumor effects of IL-12 inoculated locally into the tumors. These results support the notion that IP-10 and Mig contribute to the antitumor effects of IL-12 through their inhibitory effects on tumor vasculature.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738666     DOI: 10.1002/jlb.64.3.384

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  37 in total

1.  The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10.

Authors:  Keiji Tanese; Elizabeth A Grimm; Suhendan Ekmekcioglu
Journal:  Int J Cancer       Date:  2011-10-23       Impact factor: 7.396

2.  Interferon-independent, human immunodeficiency virus type 1 gp120-mediated induction of CXCL10/IP-10 gene expression by astrocytes in vivo and in vitro.

Authors:  V C Asensio; J Maier; R Milner; K Boztug; C Kincaid; M Moulard; C Phillipson; K Lindsley; T Krucker; H S Fox; I L Campbell
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Plasma IL-12 levels are suppressed in vivo by stress and surgery through endogenous release of glucocorticoids and prostaglandins but not catecholamines or opioids.

Authors:  Lee Shaashua; Ella Rosenne; Elad Neeman; Liat Sorski; Luba Sominsky; Pini Matzner; Gayle G Page; Shamgar Ben-Eliyahu
Journal:  Psychoneuroendocrinology       Date:  2014-01-07       Impact factor: 4.905

Review 4.  New insights into IL-12-mediated tumor suppression.

Authors:  S Tugues; S H Burkhard; I Ohs; M Vrohlings; K Nussbaum; J Vom Berg; P Kulig; B Becher
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

5.  Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth.

Authors:  Jaina M Patel; Vincent F Vartabedian; Erica N Bozeman; Brianne E Caoyonan; Sanjay Srivatsan; Christopher D Pack; Paulami Dey; Martin J D'Souza; Lily Yang; Periasamy Selvaraj
Journal:  Biomaterials       Date:  2015-09-28       Impact factor: 12.479

6.  Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.

Authors:  Tong Zhang; Charles L Sentman
Journal:  J Immunol       Date:  2013-01-25       Impact factor: 5.422

7.  Constitutive nuclear factor kappaB activity is required to elicit interferon-gamma-induced expression of chemokine CXC ligand 9 (CXCL9) and CXCL10 in human tumour cell lines.

Authors:  Miki Hiroi; Yoshihiro Ohmori
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

8.  The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies.

Authors:  Irma Airoldi; Emma Di Carlo; Barbara Banelli; Lidia Moserle; Claudia Cocco; Annalisa Pezzolo; Carlo Sorrentino; Edoardo Rossi; Massimo Romani; Alberto Amadori; Vito Pistoia
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

9.  Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer.

Authors:  Nazita Yousefieh; Suzanne M Hahto; Amber L Stephens; Richard P Ciavarra
Journal:  Cancer Microenviron       Date:  2009-05-06

10.  Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.

Authors:  Jing-Hua Huang; Song-Nan Zhang; Kyung-Ju Choi; Il-Kyu Choi; Joo-Hang Kim; Min-Geol Lee; Mingul Lee; Hoguen Kim; Chae-Ok Yun
Journal:  Mol Ther       Date:  2009-09-08       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.